Concluding Remarks

被引：0
|
作者：
Louis Lasagna
机构：
[1] Tufts University,Tufts Center for the Study of Drug Development and Sackler School of Graduate Biomedical Sciences
来源：
PharmacoEconomics | 2000年 / 18卷 / Suppl 1期
关键词：
Scientific Progress; Cost Containment; Pharmaceutical Consumption; Parallel Trader; Employer Contribution;
D O I：
10.2165/00019053-200018001-00013
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：111 / 112
页数：1
相关论文
共 50 条
  • [31] Concluding remarks
    Wasserman, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S149 - S150
  • [32] Concluding Remarks
    L. Woltjer
    Astrophysics and Space Science, 1999, 265 : 569 - 572
  • [33] Concluding remarks
    Filippov, AT
    NUCLEAR PHYSICS B, 1997, : 350 - 352
  • [34] Concluding remarks
    Shimoda, K
    JOURNAL OF MICROSCOPY-OXFORD, 1999, 194 : 584 - 584
  • [35] Concluding remarks
    Binet, JL
    HEMATOLOGY AND CELL THERAPY, 1997, 39 : S51 - S52
  • [36] Concluding remarks
    Costa, M
    GUT, 2000, 47 : 88 - 88
  • [37] Concluding remarks
    Jortner, J
    FARADAY DISCUSSIONS, 2000, 115 : 431 - 442
  • [38] Concluding remarks
    Somiari, Stella
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (01) : 219 - 223
  • [39] Concluding remarks
    Malcolm Lader
    Journal of Neurology, 1997, 244 : S46 - S47
  • [40] Concluding remarks
    Federici, G.
    Donne, A. J. H.
    FUSION ENGINEERING AND DESIGN, 2022, 178
12345